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Abstract
Weevaluatedmagnetic resonance imaging (MRI) voxel heterogeneity following trastuzumab and/or cisplatin in aHER2+
esophageal xenograft (OE19) as a potential response biomarker. OE19 xenografts treated with saline (controls),
monotherapy, or combined cisplatin and trastuzumabunderwent 9.4-TMRI. TumorMRIparametricmapsof T1 relaxation
time (pre/post contrast), T2 relaxation time, T2* relaxation rate (R2*), and apparent diffusion coefficient obtained before
(TIME0), after 24 hours (TIME1), and after 2 weeks of treatment (TIME2) were analyzed. Voxel histogram and fractal
parameters (from thewhole tumor, rim and center, and as a ratio of rim‐to‐center) were derived. Tumorswere stained for
immunohistochemical markers of hypoxia (CA-IX), angiogenesis (CD34), and proliferation (Ki-67). Combination therapy
reduced xenograft growth rate (relative change, +0.58 ± 0.43 versus controls, +4.1 ± 1.0;P = 0.008).More spatially
homogeneous voxel distribution between the rim to center was noted after treatment for combination therapy versus
controls, respectively, for contrast-enhanced T1 relaxation time (90th percentile: ratio 1.00 versus 0.88, P = 0.009), T2
relaxation time (mean: 1.00 versus 0.92, P = 0.006; median: 0.98 versus 0.91, P = 0.006; 75th percentile: 1.02 versus
0.94, P = 0.007), and R2* (10th percentile: 0.99 versus 1.26, P = 0.003). We found that combination and trastuzumab
monotherapy reducedMRI spatial heterogeneity and growth rate compared to the control or cisplatin groups, the former
providing adjunctive tumor response information.
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Esophageal cancer is the eighth commonest cancer worldwide [1].
Outcome remains poor with a 5-year overall survival rate of 18% in all
patients [2]. Neoadjuvant chemotherapy and chemoradiation have been
shown to improve survival in patients with resectable cancer [3–5]. The
addition of trastuzumab, an anti‐human epidermal growth factor receptor
2 (HER2) monoclonal antibody, to standard chemotherapy improves
overall survival in HER2-positive advanced gastroesophageal adenocar-
cinoma compared to chemotherapy alone [6].
One of the challenges in clinical practice is how best to image the spatial
and temporal intratumoral changes with treatment.Qualitative (decrease in
metabolic activity) and semiquantitative (standardized uptake value:
uptake/[injected dose/patient weight]) metabolic assessment with [18F]
fluorodeoxyglucose positron emission tomography has improved on the
sensitivity and specificity of computed tomography size-based response
assessment in the neoadjuvant setting [7]. However, with the advent of
hybrid positron emission tomography/magnetic resonance imaging (MRI)
scanners, there has been renewed interest in the additional potential ofMRI
for assessing esophageal cancer [8,9]. MRI reflects the soft tissue anatomy
well [10], has no radiation burden, and offers a multiparametric capability
beyond anatomical evaluation. For example, diffusion-weighted and
dynamic contrast-enhanced MRI sequences reflecting intratumoral water
diffusion (a surrogate for cellular volume) and vascularization (a surrogate
for angiogenesis), respectively, have shown clinical potential following
chemotherapy and/or chemoradiation in esophageal cancer [11–14].
We hypothesize that conventional chemotherapy (cisplatin) and
targeted therapy (trastuzumab) cause distinctive phenotypic and
biological changes within the tumor spatially over the course of
treatment, reflecting their specific mechanisms of action and
downstream effects. This treatment-related change may be captured
by image heterogeneity analysis on a per-voxel basis, also known as
image texture analysis. We suggest that in vivo spatial changes in the
image texture may augment standard size-based response evaluation
and complement histopathological evaluation in clinical practice [15].
Thus, as proof of principle, we aimed to evaluate the sequential changes
in intratumoral MRI spatial heterogeneity following trastuzumab and/or
cisplatin therapy in a HER2-expressing esophageal adenocarcinoma
xenograft (OE19) and to compare this with histopathological changes in
angiogenesis, hypoxia, and cellular proliferation.
Materials and Methods
Xenograft Model
All experiments were approved by our institutional review board and
performed in accordance with the UK Home Office Animals (Scientific
Procedures) Act 1986. TheHER2-expressingOE19 cells were cultured in
RPMI 1640 medium (Sigma-Aldrich, St Louis, MO) supplemented with
2 mM L-glutamine and 10% fetal bovine serum. Cells were incubated at
37°C in a humidified environment with 5% carbon dioxide. Approxi-
mately 5 × 106 OE19 cells, in serum-free media mixed with Cultrex
basement membrane extract (Trevigen Inc., Gaithersburg, MD) 1:1 to a
final volumeof 8mg/ml,were injected subcutaneously into the right flanks
of 6- to 8-week-old female severe combined immunodeficient mice
(Charles River Laboratories International, Inc.). Animals were monitored,
and bidimensional measurements were obtained using a digital caliper.
Once the tumors reached aminimumdiameter of 8mm, the animals were
treated with intraperitoneal sterile saline (control group), cisplatin 4mg/kg
body weight once a week (cisplatin monotherapy group), trastuzumab 20
mg/kg twice a week (trastuzumab monotherapy group), or a combination
of cisplatin 4 mg/kg once a week and trastuzumab 20mg/kg twice a week
(combination therapy group). Tumors were excised after 2 weeks of
therapy and were fixed in 10% buffered formalin before being embedded
in paraffin for immunohistochemistry.
In Vivo Imaging
MRI was performed with a 9.4-T MRI system (Bruker, Karlsruhe,
Germany). The animals in each of the four groups (controls, cisplatin,
trastuzumab, and combination) were anesthetized using inhalational
isoflurane (2%-4%) and 1 l/min oxygen during MRI. A high-resolution
T1 relaxation time map with and without intravenous administration of
gadopentetate dimeglumine 0.1 mmol/kg (Magnevist; Bayer HealthCare
Pharmaceuticals Inc., Germany), T2 relaxation time map, R2* map, and
apparent diffusion coefficient (ADC) map were generated from the MRI
acquisitions. Table 1 shows the MR acquisition parameters. Each animal
was imaged at three time points: before treatment (TIME0), 24 hours
after the first intraperitoneal therapy injection (TIME1), and after
completion of 2 weeks of intraperitoneal treatment (TIME2).
Image Analysis
All the MR parametric maps were analyzed using in-house software
implemented under the MATLAB (The MathWorks Inc., Natick, MA)
platform.Whole tumor volumes of interest (VOIs)were delineated by a single
observer (C. Y.). Tumor volumes were derived from the T1 images.
Three-dimensional differential analysis of the tumor rimand tumor centerwas
also performed given the inhomogeneous tumormorphology.The tumor rim
was defined as the outer 3.5mm(T1,T2,R2*maps) or outer 4.6mm(ADC
map) of a tumor, reflecting the slightly different voxel size of the ADC map.
For tumorswith volumesbelow themedian value, a 2.3-mmrimwas required
to allow adequate sampling of the rim versus center on the ADC maps.
First-order statistical histogram and fractal analysis of T1, T2, R2*, and
ADC voxels were analyzed, and the following parameters were derived for
whole tumor, tumor rim, and tumor center on each parametric map,
Table 1. MRI Acquisition Parameters
Parameters T1-Weighted T2-Weighted Diffusion-Weighted R2*
Pulse sequence Rapid acquisition rapid echo with variable
repetition time (RARE-VTR)
Multislice multiecho (MSME) Echo planar Multigradient echo (MGE)
Respiratory gating No No No Yes
Repetition time (ms) 193.44, 478.4, 878.44, 1555.502, 5000 2500 3000 1500
Echo time (ms) 6.16 13 TEs from 7.4 to 98.02 16.81 First TE 3.5 ms with 4-ms echo spacing
Field of view (mm) 30 × 30 30 × 30 30 × 30 30 × 30
Matrix 256 × 256 256 × 256 128 × 128 256 × 256
Number of signal averages 1 1 4 1
b values (s/m2) Not applicable Not applicable 100, 250, 500, 750, 1000 Not applicable
Spatial resolution (mm/voxel) 0.117 × 0.117 0.117 × 0.117 0.234 × 0.234 0.117 × 0.117
Slice thickness (mm) 1 1 1 1
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respectively: mean, median, maximum, range, standard deviation,
kurtosis, skewness, entropy, energy, 10th percentile, 25th percentile,
75th percentile, 90th percentile, mean fractal dimension, and fractal
lacunarity (Table A1 in Appendix 1) [16–18].
The ratio of all MR parameters (apart from skewness) between
tumor rim and tumor center at each time point was defined as:
Absolute value in tumor rim at TIMEn
Absolute value at tumor center at TIMEn
where n = 0, 1, or 2.
Ratios equal to 1 indicate homogeneous voxel distribution, whereas
ratios greater or less than 1 indicate more inhomogeneous voxel
distribution between rim and center.
As skewness could be positive or negative, the absolute differences
between the skewness values within tumor rim and tumor center were
obtained instead of the above ratios:
Absolute value in tumor rim at TIMEnð Þ
− absolute value in tumor center at TIMEnð Þ
where n = 0, 1 or 2.
Ratio = 0 indicates homogeneous voxel distribution, whereas
ratios greater or less than 0 indicate more inhomogeneous voxel
distribution between rim and center.
Relative proportional volumetric changes (Δ) between TIME2-TIME0
were calculated as follow:
Absolute value at TIME2−absolute value at TIME0
Absolute value at TIME0
Pathological Tumor Response
Excised tumors were fixed in 10% buffered formalin before being
embedded in paraffin for immunohistochemistry. Contiguous 5-μm
sections of formalin-fixed paraffin-embedded tumors were obtained for
hematoxylin and eosin (H&E) and immunohistochemical staining of
CA-IX, CD34, and Ki-67 (see Appendix 2 for further details). The ratios
of necrotic and fibrotic areas over the whole tumor H&E section were
quantified and categorized as minimal (ratio b 0.1), moderate (ratio
0.1-0.5) and extensive (ratio N 0.5). The tumor regression grade (TRG)
was assessed by a pathologist (F. C.) as follows: TRG1, absence of residual
cancer and extensive fibrosis; TRG2, presence of occasional cancer cells
scattered through the fibrosis; TRG3, increased residual cancer cells but
fibrosis still predominated; TRG4, residual cancer cells outgrowing
fibrosis; and TRG5, absence of regressive changes [19].
Histological Quantification
The CA-IX hypoxia fraction (HF), Ki-67 proliferative fraction
(PF), and CD34 microvessel density (MVD) were quantified (see
Appendix 2 for further details).
The ratios of positive immunohistochemical staining between
tumor rim and center were defined as:
HF;PF;or MVD in tumor rim
HF;PF;or MVD in tumor center
Statistical Analysis
The Kruskal-Wallis test was used to compare the MRI and
histopathological whole tumor parameters and ratios between the rim
and center between the treatment groups. A Bonferroni correction
Figure 1. T1 relaxation time maps showing the volumetric changes in control-treated tumor at (A) TIME0 and (B) TIME2, and
combination-treated tumor at (C) TIME0 and (D) TIME2.
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factor of 5 was applied to account for multiple MR sequences used. A
less conservative correction factor was used due to the exploratory
nature of this study. A P value b 0.01 was considered statistically
significant. All statistical analysis was performed using the IBM SPSS
Statistics software version 22 (IBM, Armonk, NY).
Results
From a total of 27 animals, 4 (1 from the cisplatin, 3 from the
combination groups) did not have TIME2 imaging due to logistical
reasons but were included in the TIME1-TIME0 MR analysis. The
remaining 23 animals were included in all analyses (5 in the control, 5 in
the cisplatin, 5 in the trastuzumab, and 8 in the combination groups).
Tumor Control
At TIME2, there was a significantly reduced growth rate in animals
treated with trastuzumab (average relative proportional change in
volume, Δ: +1.3 ± 1.2) and combination (Δ +0.6 ± 0.4) therapy
compared to the control (Δ +4.1 ± 1.0) and cisplatin (Δ +2.4 ± 1.7)
groups (P = 0.008) (Figure 1).
Pathological Tumor Response
A greater proportion of tumors in the combination (75%) and
trastuzumab (60%) groups showed some degree of pathological response
(TRG4) compared to none in the control group (Figure 2A).Moderate to
extensive intratumoral necrosis was found in all cisplatin-treated tumors
(n = 5) and themajority of controls (n = 3) (Figure 2B). In contrast, there
was less necrosis in the combination-treated tumors, but this group
demonstrated a greater degree of intratumoral fibrosis compared to
control and cisplatin groups (Figures 2C and 3).
Intratumoral Spatial Heterogeneity Between Treatment Groups
MRI. At TIME1, the distribution of contrast-enhanced T1 90th
percentile values was different between the rim and center between
treatment groups, with the combination group showing a more
homogeneous distribution, whereas T1 values were lower in the rim
compared to tumor center in other groups (average ratio 1.00, 95%
confidence interval [CI] 0.69-1.07) compared to other groups
(average ratio: cisplatin 0.91, 95% CI 0.82-0.99; trastuzumab 0.76,
95% CI 0.63-0.90; control 0.88, 95% CI 0.94-1.06) (P = 0.009)
(Figure 4). There were no early (TIME1) spatial differences in R2*,
T2, and ADC distribution between treatment groups. See Appendix
3 for the results of all MRI parameters.
At TIME 2, after completion of treatment, there was a difference in
the spatial variation of R2* 10th percentile between the rim and
center: the combination (average ratio 0.99, 95% CI 0.89-1.09) and
trastuzumab-treated tumors (average ratio 0.93, 95% CI 0.71-1.14)
showed more homogeneous R2* values compared to control (average
ratio 1.26, 95% CI 1.07-1.45) and cisplatin-treated tumors (average
ratio 1.22, 95% CI 1.10-1.33) (P = 0.003), where higher rim R2*
values were noted (Figure 5).
Figure 2. Pathological response according to treatment groups: (A) tumor regression grade, (B) intratumoral necrosis, and (C) intratumoral
fibrosis.
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There were also significant spatial differences in T2 values after
treatment. Overall, the combination and trastuzumab groups showed
a more homogeneous distribution of T2 values between tumor center
and rim compared to the control and cisplatin groups, which showed
lower T2 values in the rim compared to the center: T2 mean (average
ratio: control 0.92, 95% CI 0.89-0.95; cisplatin 0.93, 95% CI
0.89-0.97; trastuzumab 0.99, 95% CI 0.94-1.04; combination 1.00,
95% CI 0.97-1.04) (P = 0.006) (Figure 6A), T2 median (average
ratio: control 0.91, 95% CI 0.88-0.94; cisplatin 0.92, 95% CI
0.88-0.96; trastuzumab 0.97, 95% CI 0.93-1.01; combination 0.98,
Figure 3. H&E sections showing extensive intratumoral necrosis (black arrows) in (A) cisplatin- and (B) control-treated tumors, and (C, D)
evidence of fibrosis (black arrows) in combination-treated tumors.
Figure 4. Box plot showing the contrast-enhanced T1 90th percentile tumor rim-to-center ratios at TIME1 between treatment groups.
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95% CI 0.95-1.01) (P = 0.006) (Figure 6B), and T2 75th percentile
(average ratio: control 0.94, 95% CI 0.90-0.97; cisplatin 0.95, 95%
CI 0.90-1.00; trastuzumab 1.00, 95% CI 0.95-1.05; combination
1.02, 95% CI 0.99-1.05) (P = 0.007) (Figure 6C). There were no
spatial ADC differences between treatment groups.
Histopathology. There was significant spatial difference in Ki-67
(P = 0.005) expression between treatment groups (Figure 7). The
combination-treated tumors showed a more homogeneous intratu-
moral Ki-67 expression (average ratio: 0.90, 95% CI 0.71-1.09),
suggesting less proliferative spatial variation after treatment compared
to the monotherapy groups (cisplatin: 0.63, 95% CI 0.45-0.81 and
trastuzumab: 0.59, 95% CI 0.45-0.74). There was no significant
difference in spatial heterogeneity of CD34 and CA-IX expression
between treatment groups (Table A7 in Appendix 4).
Whole Tumor Parameters Between Treatment Groups
MRI. There were no significant differences in early TIME1MRI
parameters between treatment groups. Posttreatment whole tumor
TIME2 T2 SDH was greater in the combination (average 12.16, 95%
CI 10.22-14.10) and trastuzumab-treated tumors (average 12.25,
95% CI 7.84-16.65) compared to the cisplatin (average 8.42, 95%
CI 7.25-9.61) and control groups (average 9.60, 95% CI 9.00-10.19)
(P = 0.004). There were no significant differences in whole tumor
T1, ADC, and R2* parameters between treatment groups.
Histopathology. Whole tumor pathological expression of Ki-67,
CD34, and CA-IX did not differ between treatment groups (Table
A8 in Appendix 4).
Discussion
To our knowledge, there has been no published literature evaluating
the sequential changes in image spatial heterogeneity (so-called
“image texture”) and its association with histopathology in
trastuzumab- and/or cisplatin-treated esophageal cancer, both of
which form the backbone of systemic therapy in this disease. In our
xenograft study, we found spatial differences between the tumor rim
and center that were not captured by whole tumor metrics.
A decrease in MRI intratumoral spatial heterogeneity following
combination and trastuzumab therapy was observed. In particular,
contrast-enhanced T1 relaxation time, T2 relaxation time, and T2*
relaxation rate voxels were more uniformly distributed between the tumor
rimand center after 2 weeks of intraperitoneal combination and trastuzumab
monotherapy. In contrast, untreated controls demonstrated greater voxel
heterogeneity with higher R2* values but decreased contrast-enhanced T1
and T2 relaxation times within the tumor rim compared to tumor center,
compatiblewith greater contrast delivery/leakage but increasedhypoxia in the
rim. Ki-67 expression was also more homogeneous in the combination
group. In contradistinction, there was no difference in whole tumorMRI or
pathological parameters between the four groups.
While differential tumor rim to center expression of growth factors
and response to systemic therapy have been shown in other cancers
[15,20,21], few studies have investigated imaging with pathology.
Eichhorn et al. assessed the imaging and pathological tumor
microcirculation in tumor rim and center after vascular disruptive
agent (VDA) therapy (ZD6126) in the Lewis lung carcinoma
xenograft model [21]. The group performed contrast-enhanced
ultrasound at 24 hours after VDA therapy and stained the excised
tumors for CD31. They showed that tumor rim had greater rate of
signal increase, change in signal intensity from baseline to initial peak,
and also CD31 MVD after treatment compared to the tumor center.
In a study that evaluated epidermal growth factor receptor (EGFR)
expression in 386 resected colorectal cancers, 74% of tumors showed
concordance of EGFR expression between tumor center and rim [20]. A
greater proportion of tumor rim was EGFR positive (58%) compared to
46% of tumor centers. In addition, a greater EGFR expression in tumor
rim relative to tumor center, which was found in 25% of patients, was
associated with inferior survival in this patient cohort.
Nguyen et al. evaluated the pathological spatial variation of
vascular, angiogenic, hypoxia, and epithelial-to-mesenchymal
Figure 5. Box plot showing the R2* 10th percentile tumor rim-to-center ratios at TIME2 between treatment groups.
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Figure 6. Boxplots showing the T2 tumor rim-to-center ratios at TIME2between treatment groups: (A)mean, (B)median, and (C) 75thpercentile.
Figure 7. Box plot showing the Ki-67 tumor rim-to-center ratios between the groups.
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transition marker expressions between tumor rim and center in a
murine colorectal metastatic model with and without VDA therapy
(OXi4503) [15]. In the untreated tumor model, the tumor center had
greater CD34 microvessel density compared to the tumor rim.
However, vessels in the rim were more mature and stable as shown by
increased alpha smooth muscle actin staining of pericytes compared
to the tumor center. The rim was also less hypoxic as defined by
pimonidazole staining and showed greater mesenchymal transition
compared to the tumor center. Following treatment with OXi4503,
the tumor rim showed less vascular endothelial cell and tumor cell
apoptosis, and higher cellular proliferation compared to the tumor
center up to 24 hours posttreatment. These changes disappeared as
tumors regained proliferative capacity after 5 days. These results
suggest that differential inherent and treatment-related imaging and/
or pathological spatial changes may have prognostic and predictive
implications. An increase in peripheral epithelial-to-mesenchymal
transition could lead to increased invasive and metastatic potential.
Similarly, residual remnant rim of proliferative tumor cells may
harbor resistant subclones resulting in treatment failure.
Overall, our results appear consistent with previous studies that
showed differential spatial treatment-related effects associated with
targeted therapy. In our study, untreated tumors demonstrated more
heterogeneous MR voxels between the tumor rim and center with
higher R2* relaxation rate (associated in part with increased
deoxyhemoglobin concentration) but reduced postcontrast T1
relaxation time (related to greater vascularization/vascular permeabil-
ity) and T2 relaxation time values at the periphery, whereas
combination-treated tumors were more homogeneous.
Imaging heterogeneity assessed by agnostic approaches has a
clinical potential to identify responders/nonresponders at an earlier
time point for intensification of treatment in esophageal cancer.
Nevertheless, we acknowledge that it will be challenging to assess
differential rim and center imaging characteristics in an early primary
esophageal tumor. However, a significant proportion of patients will
present with locally advanced tumors. We also acknowledge that our
study has several limitations. A relatively small sample size will limit
the statistical power for some observations. The imaging time points
used in this study were chosen to represent early and late response
assessment, similar to that used in the clinical setting [22,23]. The
lack of significant MRI changes at 24 hours post–first therapy in this
study suggests that there were no “hyperacute” MRI changes that
could be detected following intraperitoneal trastuzumab and
cisplatin therapy in a mouse xenograft model. It is possible that
this could be due to the route of drug delivery used. Hence, we
suggest that an early imaging time point in a xenograft model treated
with intraperitoneal treatment protocol such as the one used in this
study may be best performed after a week of therapy to elicit clinically
relevant early imaging treatment changes to parallel what is done in
the clinical setting. Lastly, our study was performed on a 9.4-T
small-animal MR scanner and not a clinical scanner, but our study
should be regarded as proof of principle of the potential differential
therapeutic MRI effects.
In conclusion, our study showed that the combination of
trastuzumab and cisplatin therapy was most effective in slowing
tumor growth rate in a HER2+ esophageal adenocarcinoma
xenograft. Our findings suggest that trastuzumab therapy, either
alone or in combination with cisplatin, resulted in greater MR spatial
homogeneity compared to untreated/cisplatin-treated tumors. As-
sessment of intratumoral spatial heterogeneity across the rim and
center has the potential to augment standard imaging assessment
following neoadjuvant chemotherapy in esophageal cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2017.03.006.
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